AAA
CRVS icon

Affinity Asset Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Affinity Asset Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,000
Closed -$242K – 58
2021
Q3 		$242K Buy
+50,000
New +$148K 0.06% 71

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Affinity Asset Advisors's CRVS Position: Q4 2021 in Review

Affinity Asset Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q4 2021, closing a stake of 50,000 shares — an estimated $242K sold.

Affinity Asset Advisors first reported a position in CRVS in Q3 2021 and held it in 1 quarter. The position peaked at $242K in Q3 2021. 62 funds tracked by Wall St. Rank hold CRVS as of Q4 2021.

  • Affinity Asset Advisors reported no remaining Corvus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Affinity Asset Advisors sold 50,000 Corvus Pharmaceuticals shares in Q4 2021, an estimated $242K.
  • Affinity Asset Advisors first reported a position in Corvus Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Affinity Asset Advisors's Corvus Pharmaceuticals position peaked at $242K in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2021.

Based on Affinity Asset Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.